niacinamide has been researched along with Adenocarcinoma, Bronchiolo-Alveolar in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Adenocarcinoma, Bronchiolo-Alveolar: A carcinoma derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers." | 2.77 | A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. ( Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA, 2012) |
| "Sorafenib is a small-molecule multitargeted kinase inhibitor that blocks the activation of C-RAF, B-RAF, c-KIT, FLT-3, RET, vascular endothelial growth factor receptor 2 (VEGFR-2), VEGFR-3 and platelet-derived growth factor receptor β." | 2.76 | Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study. ( Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G, 2011) |
| " The majority of adverse events (AEs) were Grade 1-2 in severity." | 2.76 | Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. ( Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, CY | 1 |
| Chao, TT | 1 |
| Tai, WT | 1 |
| Chang, FY | 1 |
| Su, WP | 1 |
| Chen, YL | 1 |
| Chen, PT | 1 |
| Weng, CY | 1 |
| Yuan, A | 1 |
| Shiau, CW | 1 |
| Yu, CJ | 1 |
| Chen, KF | 1 |
| Smit, EF | 1 |
| Dingemans, AM | 1 |
| Thunnissen, FB | 1 |
| Hochstenbach, MM | 1 |
| van Suylen, RJ | 1 |
| Postmus, PE | 1 |
| Gridelli, C | 1 |
| Morgillo, F | 1 |
| Favaretto, A | 1 |
| de Marinis, F | 1 |
| Chella, A | 1 |
| Cerea, G | 1 |
| Mattioli, R | 1 |
| Tortora, G | 1 |
| Rossi, A | 1 |
| Fasano, M | 1 |
| Pasello, G | 1 |
| Ricciardi, S | 1 |
| Maione, P | 1 |
| Di Maio, M | 1 |
| Ciardiello, F | 1 |
| Adjei, AA | 1 |
| Blumenschein, GR | 1 |
| Mandrekar, S | 1 |
| Hillman, S | 1 |
| Gatzemeier, U | 1 |
| Heigener, D | 1 |
| Wakelee, HA | 1 |
| Lee, JW | 1 |
| Hanna, NH | 1 |
| Traynor, AM | 1 |
| Carbone, DP | 1 |
| Schiller, JH | 1 |
3 trials available for niacinamide and Adenocarcinoma, Bronchiolo-Alveolar
| Article | Year |
|---|---|
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combine | 2011 |
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulf | 2011 |
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic | 2012 |
2 other studies available for niacinamide and Adenocarcinoma, Bronchiolo-Alveolar
| Article | Year |
|---|---|
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cel | 2014 |
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulf | 2010 |